First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Esophageal Neoplasms Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03881111
• Other study ID #: 3475-590 China Extension
• Secondary ID: 2017-000958-1917
• Status: Withdrawn
• Phase: Phase 3
• Start date: January 21, 2019
• Est. completion date: May 11, 2022

Study information

• Verified date: February 2020
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Chinese extension study is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in a Chinese cohort of participants with locally advanced or metastatic esophageal carcinoma.

The primary efficacy hypotheses are that both progression-free survival (PFS), according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and determined by blinded independent central review, and overall survival (OS) are superior with pembrolizumab plus chemotherapy compared with placebo plus chemotherapy in all Chinese participants as well as Chinese participants whose tumors are programmed cell death-ligand 1 (PD-L1)-positive.

Description:

The Chinese extension to MK-3475-590 (NCT03189719) will enroll a total of approximately 90 participants.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 11, 2022
• Est. primary completion date: May 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Has histologically- or cytologically-confirmed diagnosis of locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction (EGJ)

• Has measurable disease per RECIST 1.1 as determined by the local site investigator/radiology assessment

• Eastern Cooperative Group (ECOG) performance status of 0 to 1

• Can provide either a newly obtained or archival tissue sample for PD-L1 by immunohistochemistry analysis

• Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to randomization and be willing to use an adequate method of contraception (e.g. abstinence, intrauterine device, diaphragm with spermicide, etc.) for the course of the study through 120 days after the last dose of study treatment and up to 180 days after last dose of cisplatin

• Male participants of childbearing potential must agree to use an adequate method of contraception (e.g. abstinence, vasectomy, male condom, etc.) starting with the first dose of study treatment through 120 days after the last dose of study treatment and up to 180 days after last dose of cisplatin, and refrain from donating sperm during this period

• Has adequate organ function

Exclusion Criteria:

• Has locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy (as determined by local investigator)

• Has had previous therapy for advanced/metastatic adenocarcinoma or squamous cell cancer of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ

• Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment

• Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early-stage cancers (carcinoma in situ or Stage 1) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, in situ breast cancer that has undergone potentially curative therapy, and in situ or intramucosal pharyngeal cancer

• Has known active central nervous system metastases and/or carcinomatous meningitis.

• Has an active autoimmune disease that has required systemic treatment in past 2 years

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment, or has a history of organ transplant, including allogeneic stem cell transplant

• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis, or has an active infection requiring systemic therapy

• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication and up to 180 days after last dose of cisplatin

• Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor or has previously participated in a pembrolizumab (MK-3475) clinical trial

• Has severe hypersensitivity (= Grade 3) to any study treatment (pembrolizumab, cisplatin, or 5-FU) and/or any of its excipients

• Has a known history of active tuberculosis (TB; Mycobacterium tuberculosis) or human immunodeficiency virus (HIV) infection

• Has known history of or is positive for hepatitis B or hepatitis C

• Has received a live vaccine within 30 days prior to the first dose of study treatment

• Has had radiotherapy within 14 days of randomization. Participants who received radiotherapy >14 days prior to randomization must have completely recovered from any radiotherapy-related AEs/toxicities

Related Conditions & MeSH terms

• Esophageal Neoplasms

Intervention

Biological:
• Pembrolizumab
200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.

Drug:
• Placebo
Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
• Cisplatin
80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
• 5-FU
800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital ( Site 0100)	Beijing
China	Peking Union Medical College Hospital ( Site 0123)	Beijing	Beijing
China	Jilin Cancer Hospital ( Site 0101)	Changchun	Jilin
China	Hunan Cancer Hospital ( Site 0105)	Changsha	Hunan
China	Fujian Provincial Cancer Hospital ( Site 0104)	Fuzhou
China	Guangdong General Hospital ( Site 0103)	Guangzhou	Guangdong
China	Zhejiang Cancer Hospital ( Site 0116)	Hangzhou	Zhejiang
China	The Affiliated Tumour Hospital of Harbin Medical University ( Site 0102)	Harbin	Heilongjiang
China	Anhui Provincial Hospital ( Site 0106)	Hefei	Anhui
China	The First Affiliated Hospital of Anhui Medical University ( Site 0112)	Hefei	Anhui
China	Jiangsu Cancer Hospital ( Site 0117)	Nanjing	Jiangsu
China	PLA Cancer Centre of Nanjing Bayi Hospital ( Site 0110)	Nanjing	Jiangsu
China	Zhongda Hospital Southeast University ( Site 0125)	Nanjing	Jiangsu
China	Fudan University Shanghai Cancer Center ( Site 0108)	Shanghai
China	Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0114)	Shanghai
China	Shanghai Chest Hospital ( Site 0111)	Shanghai
China	Tongji Medical College Huazhong University of Science and Technology ( Site 0109)	Wuhan
China	The First Affiliated Hospital of Xi an Jiaotong University ( Site 0120)	Xi'an	Shannxi
China	The First Affiliated Hospital of Xiamen University ( Site 0119)	Xiamen	Fujian
China	Henan Cancer Hospital ( Site 0107)	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants	PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first. For this analysis, PFS will be assessed in all participants.	Up to 2 years
Primary	PFS per RECIST Version 1.1 in PD-L1 biomarker-positive participants	PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first. For this analysis, PFS will be assessed in PD-L1 biomarker-positive participants.	Up to 2 years
Primary	Overall Survival (OS) in all participants	OS is defined as the time from randomization to death due to any cause. For this analysis, OS will be assessed in all participants.	Up to 2 years
Primary	OS in PD-L1 biomarker-positive participants	OS is defined as the time from randomization to death due to any cause. For this analysis, OS will be assessed in PD-L1 biomarker-positive participants.	Up to 2 years
Secondary	Objective Response Rate (ORR) per RECIST 1.1 in all participants	ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: =30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this analysis, ORR will be assessed in all participants.	Up to 2 years
Secondary	ORR per RECIST 1.1 in PD-L1 biomarker-positive participants	ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: =30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this analysis, ORR will be assessed in PD-L1 biomarker-positive participants.	Up to 2 years
Secondary	Duration of Response (DOR) per RECIST 1.1 in all participants	For participants who demonstrate CR (disappearance of all target lesions) or PR (=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), DOR is defined as the time from first documented evidence of CR or PR until disease progression per RECIST 1.1 based on assessments by blinded independent central review or death due to any cause, whichever occurs first. For this analysis, DOR will be assessed in all participants.	Up to 2 years
Secondary	DOR per RECIST 1.1 in PD-L1 biomarker-positive participants	For participants who demonstrate CR (disappearance of all target lesions) or PR (=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters), DOR is defined as the time from first documented evidence of CR or PR until disease progression per RECIST 1.1 based on assessments by blinded independent central review or death due to any cause, whichever occurs first. For this analysis, DOR will be assessed in PD-L1 biomarker-positive participants.	Up to 2 years
Secondary	Number of participants with an adverse event (AE)	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.	Up to 27 months
Secondary	Number of participants discontinuing study treatment due to an AE	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.	Up to 2 years
Secondary	Change from baseline in the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) Score	The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of quality of life (QOL): one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms.	Baseline, End of Treatment (~1 year)
Secondary	Change from baseline in the EORTC Quality Of Life Questionnaire Oesophageal Module (QLQ-OES18) Score	The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer. It contains 18 items and is based on four subscales—dysphagia (three items), eating (four items), reflux (two items) and pain (three items), as well as six single-item subscales—saliva swallowing, choking, dry mouth, taste, cough and speech. All items are scored using a four-point Likert scale that offers these response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores are standardized into a range of 0 to 100 by linear transformation; higher symptom scores represent a higher ("worse") level of symptoms.	Baseline, End of Treatment (~1 year)